Homocyst(e)ine and Coronary Heart Disease: Pharmacoeconomic Support for Interventions to Lower Hyperhomocyst(e)inaemia

Overview

Journal Pharmacoeconomics

Specialty Pharmacology

Date 2002 Jul 3

PMID 12093299

Citations 1

Authors

Brahmajee K Nallamothu

A Mark Fendrick

Gilbert S Omenn

Affiliations

Soon will be listed here.

Abstract

Homocyst(e)ine, a sulphur-containing amino acid, is an intermediate formed during the metabolism of the essential amino acid methionine. Biological and epidemiological evidence suggest that elevated plasma levels of homocyst(e)ine are a risk factor for atherosclerosis and coronary heart disease (CHD). In the general US population, hyperhomocyst(e)inaemia is common and most often due to mild nutritional deficiencies in the B vitamins (folic acid, vitamin B(12) and vitamin B(6)). While high homocyst(e)ine levels can be effectively lowered using folic acid and other B vitamins, it is unknown whether such vitamin therapy will lead to clinical benefits. Given that strategies for homocyst(e)ine-lowering are safe and inexpensive, however, even small reductions in CHD risk will be highly cost effective. Thus, it may be prudent for patients to ensure an adequate daily intake of dietary folic acid and other B vitamins and for physicians to screen high-risk adults such as those with established CHD as we await definitive results from ongoing clinical trials.

Citing Articles

Effects of folic acid plus levothyroxine on serum homocysteine level in hypothyroidism.

Ziaee A, Hajibagher Tehrani N, Hosseinkhani Z, Kazemifar A, Javadi A, Karimzadeh T Caspian J Intern Med. 2013; 3(2):417-20.

PMID: 24358436 PMC: 3861905.

References

Bostom A, Selhub J, Jacques P, Rosenberg I . Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour. Ann Intern Med. 2001; 135(2):133-7. DOI: 10.7326/0003-4819-135-2-200107170-00014. View

Mudd S, Skovby F, Levy H, Pettigrew K, Wilcken B, Pyeritz R . The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985; 37(1):1-31. PMC: 1684548. View

Graham I . Homocysteine in health and disease. Ann Intern Med. 1999; 131(5):387-8. DOI: 10.7326/0003-4819-131-5-199909070-00010. View

Genest Jr J, Audelin M, Lonn E . Homocysteine: to screen and treat or to wait and see?. CMAJ. 2000; 163(1):37-8. PMC: 1232548. View

Jacques P, Selhub J, Bostom A, Wilson P, Rosenberg I . The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med. 1999; 340(19):1449-54. DOI: 10.1056/NEJM199905133401901. View

Robinson K, Arheart K, Refsum H, Brattstrom L, Boers G, Ueland P . Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation. 1998; 97(5):437-43. DOI: 10.1161/01.cir.97.5.437. View

Gibson J, CARSON N, Neill D . PATHOLOGICAL FINDINGS IN HOMOCYSTINURIA. J Clin Pathol. 1964; 17:427-37. PMC: 480784. DOI: 10.1136/jcp.17.4.427. View

Eikelboom J, Lonn E, Genest Jr J, Hankey G, Yusuf S . Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med. 1999; 131(5):363-75. DOI: 10.7326/0003-4819-131-5-199909070-00008. View

Ubbink J, Vermaak W, Delport R, Van der Merwe A, Becker P, Potgieter H . Effective homocysteine metabolism may protect South African blacks against coronary heart disease. Am J Clin Nutr. 1995; 62(4):802-8. DOI: 10.1093/ajcn/62.4.802. View

10.

Boushey C, Beresford S, Omenn G, Motulsky A . A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995; 274(13):1049-57. DOI: 10.1001/jama.1995.03530130055028. View

11.

Jacques P, Bostom A, Williams R, Ellison R, Eckfeldt J, Rosenberg I . Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 1996; 93(1):7-9. DOI: 10.1161/01.cir.93.1.7. View

12.

Lentz S, Sobey C, Piegors D, Bhopatkar M, Faraci F, MALINOW M . Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest. 1996; 98(1):24-9. PMC: 507396. DOI: 10.1172/JCI118771. View

13.

Stamler J, Loscalzo J . Endothelium-derived relaxing factor modulates the atherothrombogenic effects of homocysteine. J Cardiovasc Pharmacol. 1992; 20 Suppl 12:S202-4. DOI: 10.1097/00005344-199204002-00057. View

14.

Wald N, Watt H, Law M, Weir D, McPartlin J, Scott J . Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998; 158(8):862-7. DOI: 10.1001/archinte.158.8.862. View

15.

Wilcken D, Wilcken B . The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976; 57(4):1079-82. PMC: 436752. DOI: 10.1172/JCI108350. View

16.

Nygard O, Nordrehaug J, Refsum H, Ueland P, Farstad M, Vollset S . Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997; 337(4):230-6. DOI: 10.1056/NEJM199707243370403. View

17.

Chambers J, Ueland P, Obeid O, Wrigley J, Refsum H, Kooner J . Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation. 2000; 102(20):2479-83. DOI: 10.1161/01.cir.102.20.2479. View

18.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998; 280(7):605-13. DOI: 10.1001/jama.280.7.605. View

19.

Danesh J, Lewington S . Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk. 1999; 5(4):229-32. View

20.

Taylor Jr L, Moneta G, Sexton G, Schuff R, Porter J . Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999; 29(1):8-19; discussion 19-21. DOI: 10.1016/s0741-5214(99)70345-9. View